empty
 
 
pl
Wyszukaj
Obsługa klienta
Szybkie założenie konta
Platforma handlowa
Wpłata/Wypłata
Wyszukaj
Dla Początkujących Dla Traderów Dla Partnerów Zrób sobie przerwę Informacje o InstaSpot
pl
#BGNE Return to the list of instruments #BMY

Currency converter

Biogen Inc.
149.07 USD
10 Jan 2025 19:43
Price Change (% chg)
$0
(0%)
Prev Close
Prev Close

Closing price, the previous day.
$150.5
Open
Open

Opening price.
$150.5
Day's High
Day's High

The highest price over the last trading day.
$149.78
Day's Low
Day's Low

The lowest price over the last trading day
$147.4
Week High
Week High

Price range high in the last week
$153.95
Week Low
Week Low

Price range low in the last week
$147.4
Download archive
Buy
149.07
Sell
149.07
Open the chart in full screen view
Buy
149.07
Sell
149.07
Download archive
Open the chart in full screen view

Biogen Inc. About company

Biogen Inc. is an American biopharmaceutical company founded in 1978. Initially, the company was headquartered in Switzerland, with all studies being conducted in European countries. Later, most of the company’s research centers were moved to the United States.

Biogen Inc. is engaged in the production of drugs based on DNA studies. At present, the company produces drugs used to treat multiple sclerosis, SMA, Alzheimer's disease, and other disorders.

Biogen’s market cap is $38.33 billion. Last year, its annual revenue stood at $10.981 billion, with net income at $1.556 billion.

Biogen’s shares and factors affecting their value

Its stock has been listed on the NASDAQ exchange under the ticker BIIB since 1983. The initial share price was $23.

Today, the company's shares are worth $257-$267. Over the past year, their value has ranged from $187 to $291.

When trading Biogen’s stock, traders are recommended to keep track of:

  • The products manufactured by the drugmaker are in demand. Moreover, their relevance is bound to increase in the future due to the world's aging population as well as progressive diseases among the elderly;
  • If the company passes clinical trials and receives a patent for a drug, it provides itself with an opportunity to make profits for at least 12 years, while other companies are prohibited from releasing analogues;
  • If Aducanumab receives approval as a treatment for Alzheimer's disease, the company’s capitalization will increase several times;
  • The company has good prospects in the market as it is greatly underestimated in comparison to competitors.

Nie możesz teraz rozmawiać przez telefon?
Zadaj pytanie na czacie.